Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

298.24 +1.39 (+0.47%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
54 55 Next >
Looking Into Amgen's Recent Short Interest
Via Benzinga
Analyst Ratings for Amgen
Via Benzinga
Why Are TScan Therapeutics Shares Are Shooting Higher Today
Amgen Inc (NASDAQ: AMGN) and TScan Therapeutics Inc (NASDAQ: TCRX) announced a multi-year collaboration to use TScan's proprietary target discovery platform, TargetScan, to identify the antigens recog 
Via Benzinga
TScan Therapeutics (NASDAQ: TCRX) and Amgen (NASDAQ: AMGN) Join Forces to Battle Crohn’s Disease
TScan Therapeutics, Inc. (NASDAQ: TCRX) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development 
Via Spotlight Growth
Check Out 3 Health Care Stocks With Over 3% Dividend Yields From Wall Street's Most Accurate Analysts
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease
From TScan Therapeutics, Inc.
Via GlobeNewswire
What Does Amgen's Debt Look Like?
Via Benzinga
A Look Into Amgen Inc's Price Over Earnings
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SVB, Amgen, and Signature and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
AMGN FINAL DEADLINE FRIDAY: ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Amgen Inc. Investors to Secure Counsel Before Important May 12 Deadline in Securities Class Action - AMGN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit Regulatory Compliance
2 Best Biotech Stocks to Buy Right Now
Buying pharmaceutical companies with all-around drug portfolios and pipelines is the key to success as an investor. 
Via The Motley Fool
AMGN NOTICE: TOP RANKED ROSEN LAW FIRM Encourages Amgen Inc. Investors to Secure Counsel Before Important May 12 Deadline in Securities Class Action – AMGN
From The Rosen Law Firm PA
Via GlobeNewswire
Here's How Much You Would Have Made Owning Amgen Stock In The Last 15 Years
Via Benzinga
Why Amgen Shares Are Trading Lower Today
Amgen Inc (NASDAQ: AMGN) reported Q1 FY23 sales of $6.11 b 
Via Benzinga
2 Magnificent Dividend Stocks to Buy Before the Next Recession
The healthcare sector is a good place to find recession-proof stocks. 
Via The Motley Fool
7 Blue-Chip Stocks to Buy in May 2023
While not the most exciting sector available, rising fears in the market incentivizes the best blue-chip stocks to buy. 
Via InvestorPlace
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SVB, Amgen, and Signature and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Why Amgen Stock Was Sickly Today
The company's asset-to-be reported underwhelming first-quarter results. 
Via The Motley Fool
Check Out What Whales Are Doing With AMGN
Via Benzinga
Amgen vs. Sandoz: Legal Battle Erupts Over Bone-Strengthening Drug Patents
Amgen Inc (NASDAQ: AMGN) has reportedly sued Novartis AG's (NYSE: NVS) Generic arm Sandoz on proposed versions of its bone-strengthening drugs Prolia and Xgeva containing denosumab, infringing several... 
Via Benzinga
AMGN LOSS ALERT: ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages Amgen Inc. Investors to Secure Counsel Before Important May 12 Deadline in Securities Class Action - AMGN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit Regulatory Compliance
2 Incredibly Cheap Dividend Stocks to Buy in May
These two dividend-paying pharma stocks both screen as significantly undervalued right now. 
Via The Motley Fool
Market Briefing For Tuesday, May 2 '23
Future earnings power is not as weak as 'bears' contend' but that also might mean the Fed's mistaken view they can temper inflation with another hike could provoke both a market sell-off and ensuing... 
Via Talk Markets
Analyst Sees A Multibagger, Initiates Coverage On This 'Top Notch Biosimilar Business'
Truist initiated coverage on Coherus BioSciences Inc (NASDAQ: CHRS) with a Buy rating and a  
Via Benzinga
AMGEN INC. (NASDAQ: AMGN) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amgen Inc. (NASDAQ: AMGN)
From Bernstein Liebhard LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DraftKings, SVB, and Amgen and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Amgen Inc. Investors to Secure Counsel Before Important May 12 Deadline in Securities Class Action - AMGN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit Regulatory Compliance
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies. 
Via Investor's Business Daily
Eli Lilly's Diabetes Newcomer, Mounjaro, Just Blew Sales Projections Out Of The Water
Mounjaro topped first-quarter sales expectations by more than $100 million. 
Via Investor's Business Daily
US Stocks Eye Higher Open As Meta Q1 Uplifts Tech Sector: Analyst Says 'No Earnings Recession In Cards Yet'
Tech earnings could come to the market’s rescue on Thursday, with all major index futures currently trading higher. 
Via Benzinga
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
54 55 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback